Nucleic Acid-based Differentiation and Identification of Medically Important Fungi


This invention, entailsnucleic acid-based assays, for detecting the presence of pathogenic fungi such as Histoplasma capsulatum, Blastomyces dermatitidis, Coccidioides immitis, Pneumocystis brasiliensis, and/or Penicillium marneffei within a sample. Within a healthcare setting, this particular approach can greatly reduce pathogen identification time, better direct treatments and ultimately improve patient outcomes. Further, this technology provides improved diagnostic specificity compared to serologic tests for circulating antibodies using patient serum samples- an approach that may give particularly aberrant results for immunosuppressed individuals, and who are frequently afflicted with opportunistic fungi. This technology is readily adaptable as kits used for species-specific identification of fungal pathogen infections and environmental contamination.

Potential Commercial Applications: Competitive Advantages:
  • Directing antifungal drug therapy for improved patient outcomes
  • Detection, discrimination of fungal pathogens
  • Addressing secondary infections of immunosuppressed individuals or asthmatics
 
  • Rapid, sensitive, simple and specific
  • Potential for automation and high-throughput screening
  • Easily adaptable to kit form


Development Stage:
In vitro data available

Related Invention(s):





Inventors:

Christine Morrison (CDC)  ➽ more inventions...

Jong Soo Choi (CDC)  ➽ more inventions...

Mark Lindsley (CDC)  ➽ more inventions...

Zhenyu Qin (CDC)  ➽ more inventions...


Intellectual Property:
U.S. Pat: 7,427,472 issued 2008-09-23
PCT Application No. PCT/US2002/030605
US Application No. 10/490,726

Publications:
Lindsley MD, et al. PMID 11574564

Licensing Contact:
Tara Kirby, Ph.D.
Email: tara.kirby@nih.gov
Phone: 240-669-5128

OTT Reference No: E-332-2013/0
Updated: Dec 23, 2013